Poor
Not Aligned
Patient Risk:
Moderate
Summary
Multiple AI claims are not supported by the supplied FDA label excerpts, including specific liver-injury symptom lists (e.g., dark urine, upper belly pain, fatigue/vomiting) and linking alcohol to muscle-injury risk; these unsupported expansions materially reduce label adherence.
Category Scores
Accurate Statements
Statins can cause elevated liver enzymes.
5.2 Liver Dysfunction (biochemical abnormalities; persistent elevations in serum transaminases)
Atorvastatin can raise liver enzymes.
5.2 Liver Dysfunction (clinical trial transaminase elevations)
Liver problems are a known safety consideration for statins.
5.2 Liver Dysfunction; 6 ADVERSE REACTIONS (liver enzyme abnormalities discussed)
Statins can rarely cause muscle injury.
5.1 Skeletal Muscle (rare cases of rhabdomyolysis)
Statin-associated muscle injury can range from muscle pain or weakness to rhabdomyolysis.
5.1 Skeletal Muscle (myopathy definition: muscle aches/weakness with CPK elevation; rare rhabdomyolysis)
Symptoms of serious muscle injury can include severe or persistent muscle pain, tenderness, or weakness.
5.1 Skeletal Muscle (advised to report unexplained muscle pain, tenderness, or weakness; myopathy considerations)
Unsupported Statements
Elevated liver enzymes are a sign of liver irritation.
Not characterized as 'liver irritation' in the supplied label excerpts.
Alcohol increases liver strain.
No equivalent statement in the supplied label excerpts.
Alcohol use can increase the overall risk of muscle injury.
The supplied skeletal muscle section does not link alcohol consumption to muscle-injury risk.
Heavy drinking is associated with higher risk of serious muscle injury in general.
Not stated in the supplied label excerpts.
Symptoms of liver injury can include dark urine.
Not described in the supplied label excerpts.
Symptoms of liver injury can include severe or persistent upper belly pain.
Not described in the supplied label excerpts.
Symptoms of liver injury can include unexplained severe fatigue or vomiting.
Not described in the supplied label excerpts.
Symptoms of serious muscle injury can include fever or feeling very ill.
Not described in the supplied label excerpts.
Symptoms of serious muscle injury can include dark/cola-colored urine.
The supplied label excerpts discuss rhabdomyolysis with myoglobinuria but do not provide the specific 'dark/cola-colored urine' symptom phrasing.
There is not a single universally safe number of drinks for everyone on atorvastatin.
No drink-number guidance in the supplied label excerpts.
If a person drinks, they should tell their clinician how much and how often.
No alcohol-amount counseling directive in the supplied label excerpts.
If a person drank once or in moderate amounts and feels well, they should stop further alcohol intake and continue atorvastatin as directed unless the prescriber advised otherwise.
No such alcohol-amount stepwise instruction in the supplied label excerpts.
Alcohol should be avoided if the person is experiencing symptoms that suggest liver injury.
No symptom-triggered alcohol avoidance language in the supplied label excerpts.
Alcohol should be avoided if the person has previously had serious statin side effects, especially muscle injury.
No label language provided linking prior statin adverse effects to alcohol avoidance.
Contradictions
Low
AI Statement
Label Reference
Important Omissions
Boxed warning content, contraindications beyond active liver disease, and drug interaction specifics are not assessed because the supplied label excerpts do not include those sections; however the AI response includes broad safety counseling that could be materially incomplete without those label parts.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported symptom and risk-expansion claims (including specific liver-injury symptom lists and alcohol-related muscle-injury risk) could mislead patient recognition/monitoring expectations relative to the provided label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Multiple safety and symptom-related statements are absent or not clearly supported by the supplied FDA label excerpts, including symptom enumeration and alcohol-muscle injury linkage.
Suggested Improvement
Restrict alcohol/liver content to the supplied label concepts (caution with substantial alcohol quantities and/or history of liver disease; LFT monitoring timing; contraindication for active liver disease/unexplained persistent transaminase elevations) and remove or rephrase unsupported symptom lists and alcohol-linked muscle injury risk claims not present in the excerpts.